Market Research Blog

The high prevalence of neurological disorders and small cell lung cancer is expected to boost the demand in the stereotactic planning software market. For instance, Parkinson’s disease and other movement disorders are estimated to affect 2.75 million people in the United States. According to DALY’s, in the U.S., stroke accounts for 3.58 Mn people, Alzheimer’s disease for 2.55 Mn, and migraine for 2.4 Mn.

Furthermore, increasing investments in better treatment options involving precision and artificial intelligence in the software provide impetus to the market by increasing the overall adoption rate. Patients are inclined towards safer and better treatment facilities with minimal incision. Stereotactic planning software facilitates surgeons to plan stereotactic surgery efficiently.

However, the unprecedented impact of the ongoing covid-19 pandemic has created a significant impact on the stereotactic planning software market due to a shortage of inpatient footfalls in hospitals and other centers.

Preference now is being given to the treatment of COVID-19 patients, thus halting product launches for stereotactic planning. Also, this has led to the postponement of the enrolment of the new participants is such studies. Now, with the availability and commencement of the COVID-19 vaccination, the research activities expected to resume in the near future.

Growing cases of neurological disorders, small cell lung cancer, and prostate cancer, along with an increase in patient awareness and screening, favorable reimbursement scenarios, approvals, and grants for product development are factors influencing market growth. The implementation of artificial intelligence, the use of visual improvements in real-time are some of the upcoming trends that are expected to create growth opportunities for manufacturers through the assessment period,” says the FMI Analyst

Key Takeaways from Stereotactic Planning Software Spending Analysis Market Study

• Integrated stereotactic planning solutions are expected to grow 2x by 2031 as compared to 2021 owing to ease of use and higher adoption rates.
• CT scans are projected to capture over 46% of the global market by 2031. This is attributed to inherent accuracy in identifying and localizing intracranial lesions.
• North America is the largest revenue-generating region for stereotactic planning software, with the U.S. accounting for over 79% of the regional market.
• The U.K. holds the lead in Europe, accounting for over 37% of the region through the end of 2031.
• East Asia is poised to grow at the highest CAGR of 5.3% during the forecast period with China accounting for over 62% of the market owing to the large subclinical patient pool of patients.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-6452

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Stereotactic Planning Software Spending Analysis is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Stereotactic Planning Software Spending Analysis based on solution type (Stand-alone Stereotactic Planning Solution, Integrated Stereotactic Planning Solution, Services), imaging modality (CT Images, MR Images, Angiographic Images), and end-user (hospitals, ambulatory surgical centers, cancer research institutes) across seven major regions.

Who is Winning?

Some of the leading companies operating in the stereotactic planning software spending analysis market are focusing on collaborations and mergers and acquisitions for global expansion options with a focus on emerging economies. Thus, enhancing their market presence. For instance,

• In March 2021, RaySearch Laboratories AB (publ) announced a sales agent agreement with Canon Medical Systems USA, Inc., enabling RaySearch America’s salesforce to promote Canon Medical’s Aquilion Large Bore CT and Celesteion PET/CT products.
• In March 2021, Brainlab announced the acquisition of Mint Medical GmbH. The acquisition aims to improve the structured diagnosis, analysis, and treatment of cancer and other diseases to address the demands of modern medicine and personalized treatments.

The key market players covered by FMI include Brainlab, Inc., Renishaw Inc., Inomed Inc., RaySearch Americas, Inc., Mevis Informática Médica, FHC, Inc., Integra LifeSciences Corporation, Elekta Solutions AB, and SurgiFRONT Ltd.

Stereotactic Planning Software Spending Analysis by CategoryBy Solution Type:

• Stand-alone Stereotactic Planning Solution
• Integrated Stereotactic Planning Solution
• Services
  • Consulting & Implementation
  • Training Services
  • On-demand Support Services

By Imaging Modality:

• CT Images
• MR Images
• Angiographic Images

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Cancer Research Institutes

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-6452

Weakening of pelvic floor muscles, urinary tract infections, menopause, constipation, obesity, and alcoholism are the main causes of urinary incontinence. The rising prevalence of these conditions, added to the growing elderly population, are major drivers for the global pelvic floor stimulators market.

Similarly, a high level of portability and lower costs of mobile devices in contrast to fixed devices or surgical treatments, and progressive therapeutic results and easy access to patients through over-the-counter (OTC) medical channels are expected to drive demand.

Initiatives undertaken by government and non-governmental organizations to create awareness are increasing the demand for pelvic floor stimulators. For instance, the Australian government has started a program “National Continence Management Program.”

The government of Australia also started “The continence aids payment scheme (CAPS).” COVID-19 kicked the pelvic floor stimulators demand into high gear—and this extended to consumers increasing their adoption using online sales channels. However, lack of labor, halt on transportation, and disruptions in the supply chain, has affected device availability and growth prospects for the near future.

Manufacturers are focusing on research and development activities to develop unique and technologically advanced devices with rechargeable functionality. In March 2019 InControl Medical received FDA approval for a new Attain designed for at-home use to women in the U.S. suffering from stress, urge, mixed urinary incontinence or bowel incontinence.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13187

Key Takeaways from Pelvic Floor Stimulator Market Study

• Electrical stimulators will reflect a revenue share of more than 66% with a CAGR of 9.1% owing to the high demand for treatment research for urinary incontinence.
• Urinary Incontinence holds a share of over 75% in 2021, due to the growing geriatric population which is prone to urinary incontinence.
• The U.K and Germany are leading markets in Europe, cumulatively accounting for over 45% of the regional value share, owing to consumer reliance on technology for health information.
• Driven by a matured healthcare and research sector, the U.S., will account for more than 78% of the North America market by 2031.
• China is a high potential market reflecting a 9.9% CAGR, driven by a rapidly growing consumer demographic of geriatrics.

 “Increasing prevalence of pelvic floor disorders and subsequently rising increasing awareness about the benefits electrical stimulation in the treatment of urinary incontinence are driving the adoption pelvic floor stimulators on a global scale through 2031,” says the FMI Analyst.   

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13187

Key Participant Insights

Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to expand their research and development capabilities, while increasing their sales by strengthening product portfolios in the pelvic floor stimulator market.

In August 2020, Medtronic expanded leadership to launch InterStim Micro Neurostimulator and InterStim SureScan MRI Leads, for treating bladder and bowel control conditions.

Want More Insights?

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels that provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global pelvic floor stimulator market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the pelvic floor stimulator market on basis of product type [Electrical stimulators and Magnetic Stimulators], application (Urinary Incontinence, Sexual Dysfunction and Neurodegenerative Diseases). Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.

Pelvic Floor Stimulators Market by Category

Product Type:

• Electrical stimulators
• Magnetic Stimulators

Application:

• Urinary Incontinence
• Sexual Dysfunction
• Neurodegenerative Diseases

End-User:

• Hospitals
• Ambulatory Surgical Centers
• Specialized clinics
• Homecare setting

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-13187

Rapidly growing ageing population and prevalence of obesity worldwide have led to significant rise in knee osteoarthritis cases. As per Centers for Disease Control and Prevention (CDC), osteoarthritis being the most common form of arthritis, has affected over 32.5 million US adults in 2019.

People suffering from arthritis have concerns regarding knee arthroplasty surgery and associated post-operational complications. High cost of treatment and longer hospital stays have further caused increased preference of minimally invasive surgical procedures which has minimum risks, low cost and lesser hospital stay. This is projected to increase the preference of the knee hyaluronic acid injections in order to avoid or delay knee surgical procedures.

Companies specializing in knee hyaluronic acid injections have been focusing on developing products with superior efficacy, lesser side effects and minimum patient discomfort. Knee hyaluronic acid injection product portfolio offering single, three and five injection knee hyaluronic injections along with combination injections maximizes the efficacy for upto 6 or more months in the treatment of knee osteoarthritis.

Presently, the ageing population around the world are more involved in their well-being while focusing on nutrition and self-care solutions with high quality yet affordable price. Increase in consumer spending, improved healthcare infrastructure, rising government and industry investments in research and developments is expected to stimulate market by early diagnosis, accessibility and patient affordability. All these factors are expected to create demand for knee hyaluronic acid injections market.

Key takeaways from Knee Hyaluronic Acid Injections Market study

• By product, three injection knee hyaluronic acid injections is the most lucrative segment in terms of revenue and anticipated to increase at a CAGR of more than 4% over 2021-2031.
• Among end users, ambulatory surgical centers and orthopedic clinics segment are collectively leading the market and expected to gain more than 50% of revenue share over the forecast period.
• North America will continue dominating the global knee hyaluronic acid injections market in terms of revenue in 2021, followed by Europe region.
• India is the dominant country in term of revenue for South Asia Knee Hyaluronic Acid Injections market accounting for over 70% of Market value share in 2021.
• Japan holds leading position in East Asia and is expected to account for nearly 50% of market share.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-12548

Some of the leading manufacturers of knee hyaluronic acid injections are focusing on new product development, clinical trials, speedy regulatory approvals, exclusive marketing and distribution licensing agreement strategies, thereby enhancing their market presence.

• In March 2016, Anika Therapeutics Inc., issued CE Mark approval and medical device status for its combination knee hyaluronic acid injections Cingal® for the treatment of pain associated with osteoarthritis of the knee. Cingal® is a third generation knee hyaluronic acid injections with proprietary cross-linked sodium hyaluronate and triamcinolone hexacetonide, a well-established, FDA-approved steroid to treat inflammation.
• In February 2018, Bioventus LLC extended its distribution agreement for SUPARTZ FX™ with Seikagaku Corporation to continue distributing SUPARTZ FX™ in the U. S. after the previous distribution agreement expired in May 2017. Under terms of this extension, Bioventus will continue to distribute SUPARTZ FX in the US through May 2028
• In December 2019, Fidia Farmaceutici S.p.A. introduced TRILURON™ (sodium hyaluronate) three injections knee hyaluronic acid injections in the US.

The key market players covered by FMI include Sanofi, Anika Therapeutics, Inc. (DePuy Synthes Inc.), SEIKAGAKU CORPORATION, Zimmer Biomet, BSA Institut Biochimique SA (Bioventus LLC), Fidia Farmaceutici S.p.A, Meiji Holdings Co., Ltd, (OrthogenRx), Ferring B.V, Viatris Inc., Hanmi Pharm.Co.,Ltd (Teva Pharmaceutical Industries Ltd.).

Want more insights?Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global knee hyaluronic acid injections market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on knee hyaluronic acid injections segment based on Product (Single Injection knee hyaluronic acid injections, Three Injection knee hyaluronic acid injections, Five Injection knee hyaluronic acid injections, and Next Generation(Steroid Combination) Knee hyaluronic acid injections), End User (Hospitals, Ambulatory Surgical Centres, Orthopaedic Clinics, Retail Pharmacies and Online Sales) across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-12548

Antihistamines are a class of medications that are often used to treat allergy symptoms. These medications are used to treat problems caused by an excess of histamine, a substance produced by the immune system. People who are allergic to pollen and other allergens are the most prevalent users of antihistamines. Sneezing, congestion, and itchy, runny nose can all be relieved with antihistamine sprays. They are available by prescription and include azelastine (Astelin, Astepro) and olopatadine (Patanase).

The global burden of respiratory diseases such as allergic rhinitis, chronic obstructive pulmonary disease, asthma has increased rapidly in the last three decades. In an article published in NCBI, it was reported that around 20–30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma.

Due to this growing burden, there has been an increased adoption rate of nasal antihistamines in the form of nasal sprays and nasal drops, globally. The nasal antihistamines provide rapid and effective relief from the symptoms of allergic rhinitis. Thus, the growing number of allergic rhinitis cases will propel the growth of the nasal antihistamines market in the future.

Advancements in the field of nasal drug delivery have enabled the establishment of several non-invasive approaches for treatment. Various new products such as metered dose delivery systems, innovative odorless powders and sprays, preservative-free nasal sprays and others are key drivers that will expand this industry in the forecast period.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13708

FDA approvals of various nasal sprays to switch from prescription to OTC use has led to increased independence concerning self-administration of drugs, amongst patients who suffer from allergic rhinitis. Various additions by the manufacturers to the already available product lines, especially for AR are some of the techniques used by the manufacturers to increase product penetration amongst the population.

New product launches & approvals have emerged as key growth strategies adopted by the leading players in the nasal antihistamines market. Followed by this, the acquisition was the second most key strategy adopted by the industry players. By adopting these strategies, it helped the company to expand their regional presence as well as product offerings.

For instance, In December 2020, GlaxoSmithKline launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerine as a product for the symptomatic relief of allergic rhinitis.

Such developments not only strengthens the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and helps companies to sustain the increasing competitive pressure.

Key Takeaways from Nasal Antihistamines Market Study

• By pProduct, nasal sprays accounted for the largest share of 89.0% in 2021 and are expected to continue to grow at the same trend during the forecast period.
• By age group, adults accounted for the largest share in 2021 of the nasal antihistamines market and are expected to continue to grow at the same trend during the forecast period.
• By distribution channel, the retail pharmacies segment is expected to account for the largest share of 41.0% in 2021 of the nasal antihistamines market and is expected to continue to grow at the same trend during the forecast period.
• By region, East Asia held the largest share of 23.0% in 2021 of the nasal antihistamines market. The growing awareness regarding allergies and developing healthcare infrastructure are some of the factors that fuel the high market share of this region.

“Growing prevalence of allergic rhinitis and resultant increase in adoption of nasal mode for drug delivery will drive the market growth in the next decade,” says the FMI Analyst

Scope of the Report

Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	USD Million for value
Key Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa
Key Countries Covered	US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa
Key Segments Covered	Product, Age Group, Distribution Channel, Region
Key Companies Profiled	Bayer Healthcare LLC Novartis AG Glenmark Pharmaceuticals GlaxoSmithKline Sun Pharmaceuticals Cipla Merck & Co. Viatris (Meda Pharmaceuticals) Proctor & Gamble Ascend Laboratories LLC (Alkem Laboratories) Centaur Pharmaceuticals J Pharmaceuticals Alitair Pharmaceuticals Sato Pharmaceuticals
Report Coverage	Market Forecast, brand share analysis, competition Intelligence, DROT Analysis, Market Dynamics and Challenges and Strategic Growth Initiatives

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13708

Who is Winning?

Some of the leading manufacturers of the nasal antihistamines market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

• In April 2021, Merck & Co. acquired Pandion Therapeutics, Inc which is a U.S. based clinical-stage biotechnology company for US $ 1.85 Bn. With this acquisition, Merck strategizes to identify and secure candidates with differentiated and potentially found characteristics for the clinical trials that would be required for their new product launches. This will ensure smooth conduction of clinical trials and thus help the company to expand their business.
• In April 2020, Cipla receives final approval for a generic version of Proventil® HFA Inhalation Aerosol, from the United States FDA. With this approval, the company strengthened their presence in the US pharmaceutical market

The key market players covered by FMI include Bayer Healthcare LLC, Novartis International AG, Cipla, Glenmark Pharmaceuticals, GlaxoSmithKline, Sun Pharmaceuticals, Merck & Co., Centaur Pharmaceuticals, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories LLC (Alkem Laboratories), J Pharmaceuticals, Alitair Pharmaceuticals and Sato Pharmaceuticals.